Decreased T1 Times and Impaired Myocardial Contractility in Anabolic Androgenic Steroids Users

Focal Fibrosis Clinical Trial

Official title: Decreased Myocardial Native T1 Times and Impaired Myocardial Contractility in Young Anabolic Androgenic Steroids Users

Status Completed

Clinical Trial Summary

Anabolic androgenic steroids (AAS) abuse may have a toxic on myocardium that could lead to cardiac alterations. Clinical cases reported myocardial fibrosis in AAS users. However, recent studies did not find myocardial fibrosis in AAS users using T1-mapping technique. The aim of this study was to evaluate cardiac structure by cardiovascular magnetic resonance (CMR) with late-gadolinium enhancement (LGE), cardiac T1-mapping and extracellular volume (ECV). We also evaluated the cardiac contractility in AAS users.

Clinical Trial Description

Twenty strength-trained AAS users (AASU) age 29±5 yr, 20 age-matched strength-trained AAS nonusers (AASNU), and 10 sedentary controls (SC) were enrolled.

Cardiac structure was assessed by LGE, T1-mapping and ECV. Cardiac contractility was evaluated as cardiac strain by CMR (feature tracking) and echocardiography (speckle tracking) ;

Related Conditions & MeSH terms

• Focal Fibrosis

• NCT number: NCT03862235
• Study type: Observational
• Source: University of Sao Paulo General Hospital
• Status: Completed
• Start date: April 1, 2015
• Completion date: April 1, 2017